What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.